Catalog No.
FHK28413
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Conjugation
APC
Target
IGPR-1, CD28H, CD28 homolog, Immunoglobulin and proline-rich receptor 1, TMIGD2, IGPR1, Transmembrane and immunoglobulin domain-containing protein 2
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Accession
Q96BF3
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Stability and Storage
Store at 4°C for 12 months. Protect from light. Do not freeze.
Clone ID
SAA0319
Human endogenous retrovirus-H long terminal repeat-associating 2: an emerging immune checkpoint for cancer immunotherapy., PMID:38973642
The Importance of HHLA2 in Solid Tumors-A Review of the Literature., PMID:38786018
TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors., PMID:38718110
Maintenance of caecal homeostasis by diverse adaptive immune cells in the rhesus macaque., PMID:38707998
Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer., PMID:38522775
TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells., PMID:38167704
B7-H7: A potential target for cancer immunotherapy., PMID:37290327
Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies., PMID:37069229
HHLA2 immune-regulatory roles in cancer., PMID:37011487
Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal Cancer., PMID:36982953
Protocol for evaluating antitumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model., PMID:36386885
KIR3DL3-HHLA2 and TMIGD2-HHLA2 pathways: The dual role of HHLA2 in immune responses and its potential therapeutic approach for cancer immunotherapy., PMID:35933091
NK Cells Equipped With a Chimeric Antigen Receptor That Overcomes Inhibition by HLA Class I for Adoptive Transfer of CAR-NK Cells., PMID:35585985
Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy., PMID:35439678
Expression of HHLA2, TMIGD2, and GITR in salivary gland adenoid cystic carcinoma and mucoepidermoid carcinoma., PMID:35226778
HHLA2 Activates the JAK/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells., PMID:35175496
KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target., PMID:34244312
KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1., PMID:33229411
Iron Deprivation in Human T Cells Induces Nonproliferating Accessory Helper Cells., PMID:32284314
B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling., PMID:32005952
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy., PMID:31108883
The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma., PMID:31089395
The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3., PMID:28258693
The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account., PMID:27191544
Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis., PMID:26071192
A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2., PMID:25869386
Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein., PMID:25549724
For research use only. Not for human or drug use.
